BRAF, a serine-threonine kinase, is, like KRAS, part of the Ras-Raf-MEK-ERK signalling pathway. BRAF activating mutations are present in melanomas, papillary thyroid cancers, testicular, ovarian and colorectal cancers.

​

Most common of BRAF activating somatic mutations is V600E mutation. Tumors with this mutation exhibit poor response to anti-EGFR therapy but may be sensitive to selctive inhibitors of BRAF.

​

BRAF-MMD-PCR Mutation Test Kit enables detection of V600E mutation in b-raf gene against a background of wild-type genomic DNA.